Literature DB >> 24014878

Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.

Marie C Mayer1, Constanze Breithaupt, Markus Reindl, Kathrin Schanda, Kevin Rostásy, Thomas Berger, Russell C Dale, Fabienne Brilot, Tomas Olsson, Dieter Jenne, Anne-Katrin Pröbstel, Klaus Dornmair, Hartmut Wekerle, Reinhard Hohlfeld, Brenda Banwell, Amit Bar-Or, Edgar Meinl.   

Abstract

Autoantibodies targeting conformationally intact myelin oligodendrocyte glycoprotein (MOG) are found in different inflammatory diseases of the CNS, but their antigenic epitopes have not been mapped. We expressed mutants of MOG on human HeLa cells and analyzed sera from 111 patients (104 children, 7 adults) who recognized cell-bound human MOG, but had different diseases, including acute disseminated encephalomyelitis (ADEM), one episode of transverse myelitis or optic neuritis, multiple sclerosis (MS), anti-aquaporin-4 (AQP4)-negative neuromyelitis optica (NMO), and chronic relapsing inflammatory optic neuritis (CRION). We obtained insight into the recognition of epitopes in 98 patients. All epitopes identified were located at loops connecting the β strands of MOG. The most frequently recognized MOG epitope was revealed by the P42S mutation positioned in the CC'-loop. Overall, we distinguished seven epitope patterns, including the one mainly recognized by mouse mAbs. In half of the patients, the anti-MOG response was directed to a single epitope. The epitope specificity was not linked to certain disease entities. Longitudinal analysis of 11 patients for up to 5 y indicated constant epitope recognition without evidence for intramolecular epitope spreading. Patients who rapidly lost their anti-MOG IgG still generated a long-lasting IgG response to vaccines, indicating that their loss of anti-MOG reactivity did not reflect a general lack of capacity for long-standing IgG responses. The majority of human anti-MOG Abs did not recognize rodent MOG, which has implications for animal studies. Our findings might assist in future detection of potential mimotopes and pave the way to Ag-specific depletion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24014878     DOI: 10.4049/jimmunol.1301296

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Clinical and MRI phenotype of children with MOG antibodies.

Authors:  Cristina Fernandez-Carbonell; David Vargas-Lowy; Alexander Musallam; Brian Healy; Katherine McLaughlin; Kai W Wucherpfennig; Tanuja Chitnis
Journal:  Mult Scler       Date:  2015-06-03       Impact factor: 6.312

Review 2.  [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Authors:  S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

Review 3.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

4.  A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter.

Authors:  Diego Franciotta; Antonio Uccelli
Journal:  Neurol Sci       Date:  2017-10       Impact factor: 3.307

5.  Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.

Authors:  Joachim Havla; T Kümpfel; R Schinner; M Spadaro; E Schuh; E Meinl; R Hohlfeld; O Outteryck
Journal:  J Neurol       Date:  2016-11-14       Impact factor: 4.849

6.  Myelin Oligodendrocyte Glycoprotein-IgG Contributes to Oligodendrocytopathy in the Presence of Complement, Distinct from Astrocytopathy Induced by AQP4-IgG.

Authors:  Ling Fang; Xinmei Kang; Zhen Wang; Shisi Wang; Jingqi Wang; Yifan Zhou; Chen Chen; Xiaobo Sun; Yaping Yan; Allan G Kermode; Lisheng Peng; Wei Qiu
Journal:  Neurosci Bull       Date:  2019-04-30       Impact factor: 5.203

7.  Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes.

Authors:  Maria Sepúlveda; Thaís Armangue; Eugenia Martinez-Hernandez; Georgina Arrambide; Nuria Sola-Valls; Lidia Sabater; Nieves Téllez; Luciana Midaglia; Helena Ariño; Patrick Peschl; Markus Reindl; Alex Rovira; Xavier Montalban; Yolanda Blanco; Josep Dalmau; Francesc Graus; Albert Saiz
Journal:  J Neurol       Date:  2016-05-04       Impact factor: 4.849

8.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Authors:  Michael Hecker; Brit Fitzner; Matthias Wendt; Peter Lorenz; Kristin Flechtner; Felix Steinbeck; Ina Schröder; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Cell Proteomics       Date:  2016-02-01       Impact factor: 5.911

Review 9.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 10.  B cells in MS and NMO: pathogenesis and therapy.

Authors:  Markus Krumbholz; Edgar Meinl
Journal:  Semin Immunopathol       Date:  2014-05-16       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.